<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830427</url>
  </required_header>
  <id_info>
    <org_study_id>A7881006</org_study_id>
    <nct_id>NCT00830427</nct_id>
  </id_info>
  <brief_title>A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects</brief_title>
  <acronym>A7881006</acronym>
  <official_title>A Phase IIb Randomised, Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of PF-00610355 Over 4 Weeks In Moderately Asthmatic Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and
      aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a
      daily basis for 4 weeks in subjects maintained on inhaled corticosteroid.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline trough (24 hours post-dose) FEV1.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate.</measure>
    <time_frame>week 0, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in trough FEV1.</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in FEV1 from 0 to 6 hours post-dose.</measure>
    <time_frame>week 0,week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Asthma Quality of Life Questionnaire (AQLQ-S) score.</measure>
    <time_frame>week 2, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PF-00610355.</measure>
    <time_frame>week 0, week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Asthma, Bronchial</condition>
  <condition>Lung Diseases, Obstructive</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Bronchial Diseases</condition>
  <arm_group>
    <arm_group_label>PF-00610355</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF - 00610355</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00610355</intervention_name>
    <description>100 mcg, QD, dry powder inhaler</description>
    <arm_group_label>PF-00610355</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF - 00610355</intervention_name>
    <description>600 mcg, QD, dry powder inhaler</description>
    <arm_group_label>PF - 00610355</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>QD, dry powder inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF - 00610355</intervention_name>
    <description>300 mcg, QD, dry powder inhaler</description>
    <arm_group_label>PF - 00610355</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a physician documented history or diagnosis of persistent asthma for at
             least 6 months prior to Screening Visit 1.

          -  Trough FEV1 must be 50-100% of predicted at Screening Visit 1.

          -  Subjects who have been maintained on a stable dose of ICS over the previous month
             prior to screening.

        Exclusion Criteria:

          -  Subjects who have had a severe asthma exacerbation in the 2 months prior to screening.

          -  Subjects meeting any of the criteria of 'very poorly controlled' according to the NIH
             EPR 3 guidelines.

          -  Subjects with evidence or history of cardiovascular disease including angina,
             myocardial, infarction, clinically significant cardiac arrhythmia (eg, atrial
             fibrillation, atrial flutter,supraventricular tachycardia, ventricular tachycardia),
             systemic hypertension (SBP &gt; 160 mmHg or DBP &gt;100mmHg), pulmonary hypertension or
             cerebrovascular disease (including transient ischaemic attacks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7881006&amp;StudyName=A%20Study%20To%20Examine%20The%20Safety%20And%20Efficacy%20Of%20PF-00610355%20In%20Moderately%20Asthmatic%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>asthma bronchial diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Bronchial Diseases</mesh_term>
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

